Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Omada Health made a profit per share in its latest year after a loss the year before.
Growing fast, still losing money. Revenue grew faster than 89% of peers, at an operating loss.
Revenue grew faster than 89% of peers, but the business runs at an operating loss (margin -0.1%).
Cash flow well above reported profit. Free cash flow is 5.3× reported profit.
Free cash flow is 5.3× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Little borrowing.Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
Omada Health has among the least debt in its peer group relative to shareholders' equity.
Revenue and earnings-per-share growth over one year, and revenue growth over three years.
Earnings per share growthUnavailable
Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991
3-year revenue growth42.9%
Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score 4.41Sector median: 0.0584 · MAD: 0.0840
Revenue growth47.6%
SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 4.26Sector median: 0.0609 · MAD: 0.0974
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Omada Health
Is Omada Health getting weaker?
Its latest SEC filing (Aug 7, 2026) was mixed: some things better, some worse: turned profitable over the last 12 months; operating margin rose 2.8 points to -0.1%. Its overall score is unchanged at 61/100 since Oct 28, 2026.
How is Omada Health valued vs its peers?
Priced higher than most peers relative to what it earns. Valuation scores 32/100 against 1,393 healthcare peers.EBITDA yield 0.6% vs a peer median of 4.0% (weaker than 66% of peers).EBITDA yield 0.6% vs peers 4.0% (weaker than 66% of peers).
Is Omada Health growing?
Yes, faster than most of its peers. Growth scores 93/100 against 1,393 healthcare peers.3-year revenue growth 42.9% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 42.9% vs peers 5.8% (stronger than 92% of peers).
How profitable is Omada Health?
Less profitable than most of its peers. Profitability scores 38/100 against 1,393 healthcare peers.Operating margin -0.1% vs a peer median of 7.1% (weaker than 67% of peers).Operating margin -0.1% vs peers 7.1% (weaker than 67% of peers).
How risky is Omada Health?
Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 0.00× vs a peer median of 0.22× (stronger than 95% of peers).Debt / equity 0.00× vs peers 0.22× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 7, 2026 · compared with the quarter ended Mar 31, 2026
Mixed: some things better, some worse
Turned profitable over the last 12 months
Operating margin rose 2.8 points to -0.1%
Share count up 3.0% (existing holders diluted)
Previous quarter
Latest quarter
Change
Revenue (12 months)
283.3M USD
309.8M USD
+9.3%
Net income (12 months)
−6.3M USD
4.3M USD
turned positive
Operating margin
-2.9%
-0.1%
+2.8 pts
Free cash flow (12 months)
21.5M USD
22.7M USD
+5.9%
Cash
211.8M USD
221.7M USD
+4.7%
Shares outstanding
59.4M
61.2M
+3.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2023
FY 2024
FY 2025
Change
Gross margin
57.0%
60.6%
65.7%
▲ 5.1 pts
Operating margin
-53.8%
-25.7%
-4.6%
▲ 21 pts
Net margin
-55.0%
-27.8%
-4.9%
▲ 23 pts
Return on assets (ROA)
—
-31.2%
-4.2%
▲ 27 pts
Return on equity (ROE)
—
—
-5.6%
—
Free cash flow margin
-40.8%
-20.5%
6.5%
▲ 27 pts
Current ratio
—
2.10×
3.60×
▲ 72%
Quick ratio
—
2.03×
3.54×
▲ 74%
Debt to equity
—
—
0.00×
—
Interest coverage
-14.03×
-9.69×
-4.72×
▲ 51%
OMDA price history
Price history is added with the daily price update and will appear after the next one.